Skip to main content
Marker Therapeutics, Inc. logo

Marker Therapeutics, Inc. — Investor Relations & Filings

Ticker · MRKR ISIN · US57055L1070 US Manufacturing
Open in API
Filings indexed 899 across all filing types
Latest filing 2002-08-16 Interim / Quarterly Rep…
Country US United States of America
Listing US MRKR

About Marker Therapeutics, Inc.

https://markertherapeutics.com/

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing next-generation T cell-based immunotherapies for hematologic malignancies and solid tumors. The company's core technology is its Multi-Antigen Recognizing (MAR) T cell platform, which utilizes natural, non-genetically modified T cells to recognize and kill heterogeneous tumors. This approach is designed to provide durable anti-tumor responses with a favorable safety profile. Its lead product candidate, MT-601, recognizes six tumor-specific antigens and is being evaluated in a Phase 1 study for patients with lymphoma who have relapsed or are ineligible for anti-CD19 CAR-T cell therapy. The technology was originally developed at Baylor College of Medicine.

Recent filings

Filing Released Lang Actions
10QSB/A
Interim / Quarterly Report Classification · 100% confidence The document is titled "AMENDMENT NO. 1 TO FORM 10-QSB" and is described as a "QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2002." It contains detailed interim consolidated financial statements, notes to the financial statements, management discussion and analysis, and other quarterly report items. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The presence of financial statements and management discussion confirms it is an interim or quarterly report. Therefore, the correct classification is Interim / Quarterly Report (IR).
2002-08-16 English
10QSB
Interim / Quarterly Report Classification · 100% confidence The document is a Form 10-QSB, which is a quarterly report filed pursuant to the Securities Exchange Act of 1934. It contains detailed interim consolidated financial statements, management's discussion and analysis, notes to the financial statements, and other relevant financial and operational information for the quarterly period ended June 30, 2002. The presence of unaudited interim financial statements and the explicit labeling as a quarterly report confirm that this is an Interim / Quarterly Report. The document length (15,000 characters) and content indicate it is the full report, not just an announcement or certification. Therefore, the appropriate classification is 'IR' for Interim / Quarterly Report.
2002-07-26 English
SC 13D
Major Shareholding Notification
2002-07-26 English
8-K/A
Regulatory Filings Classification · 95% confidence The document is an Amendment No. 1 to Form 8-K, a current report filed with the SEC. It details a change in control of the registrant, including acquisition activities, share exchange agreements, issuance of restricted common stock, changes in board composition, and other corporate actions. The document is not a full annual or quarterly report, nor is it an earnings release or audit report. It is a regulatory filing reporting significant corporate events and changes, typical of a Form 8-K filing. The length and detail confirm it is not a brief announcement but a substantive regulatory filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2002-07-25 English
S-8
Regulatory Filings Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the U.S. Securities and Exchange Commission. It relates to the registration of securities under the Securities Act of 1933, specifically for a stock option plan. The content includes legal opinions, indemnification clauses, and details about the securities being registered. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration and compliance, not a report or announcement of financial results or corporate governance changes. Therefore, it fits best under Regulatory Filings (RNS). The document length is substantial (over 14,000 characters), indicating it is a full filing, not a brief announcement.
2002-07-18 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the U.S. SEC, dated July 18, 2002, by GeneMax Corp. It details a change in control of the registrant due to the acquisition of GeneMax Pharmaceuticals, including share exchange agreements, issuance of restricted common stock, and changes in board composition. The document includes detailed descriptions of the acquisition, share issuance, loan agreements, and business operations post-acquisition. It is not a full annual or quarterly report, nor an earnings release or audit report. It is a regulatory filing reporting a significant corporate event (change in control) and related disclosures. The document is lengthy (15,000 characters) and contains substantive information about the transaction and corporate changes, consistent with a Current Report on Form 8-K. Therefore, the appropriate classification is Regulatory Filings (RNS).
2002-07-18 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.